Venrock Healthcare Partners

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 28
Average round size
info
The average size of a deal this fund participated in
$120M
Portfolio companies 27
Rounds per year 0.53
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.04
Exits 14
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

The fund has exact preference in a number of founders of portfolio startups. When startup sums 2 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Health Care. Among the most popular portfolio startups of the fund, we may highlight Sojournix, Corvidia, Metacrine.

The typical case for the fund is to invest in rounds with 8 participants. Despite the Venrock Healthcare Partners, startups are often financed by venBio Partners, Polaris Partners, Pappas Ventures. The meaningful sponsors for the fund in investment in the same round are Boxer Capital, RTW Investments LLC, RA Capital Management.

The increased amount of exits for fund were in 2019. The fund is constantly included in 2-6 investment rounds annually. The high activity for fund was in 2018. The real fund results show that this VC is 20 percentage points more often commits exit comparing to other companies. Deals in the range of 50 - 100 millions dollars are the general things for fund. Opposing the other organizations, this Venrock Healthcare Partners works on 9 percentage points less the average amount of lead investments.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Beagle California, Goleta, United States
BF Holdings Dudley, England, United Kingdom
China Life Private Equity Investment Beijing, Beijing, China
Chuangye Jieli China, Shanghai
Colony Latam Partners -
CWB Startup Invest China, Hong Kong, Hong Kong Island
ESM Japan Fukui, Fukui Prefecture, Japan
Henley Ventures British Columbia, Canada, Surrey
Luminary Media Nusantara -
miHoYo China, Shanghai
North East Development Capital Fund -
Novel TMT Ventures New York, New York, United States
Olist Brazil, Curitiba, Paraná
Starwood Capital Group Connecticut, Greenwich, United States
Traction Camp -
Weier Chuangye Touzi Chengguan District, China, Lhasa
Zambian venture capital -
Zhejiang Lipin Hangye Xiehui -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Dianthus Therapeutics

Biopharma
Biotechnology
Health Care
$100M19 Apr 2022 Waltham, Massachusetts, United States

Lyra Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
Wellness
$100M08 Apr 2022 Massachusetts, United States

Trevi Therapeutics

Biotechnology
Health Care
Pharmaceutical
$55M07 Apr 2022 Connecticut, United States

Mythic Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$103M15 Dec 2021 Massachusetts, United States

Ablaze Pharmaceuticals

Medical
Pharmaceutical
$75M29 Nov 2021 Jingan, Shanghai, China

RayzeBio

Biotechnology
Health Care
Medical Device
Pharmaceutical
$108M15 Jun 2021 San Diego, California, United States

Nuvalent

Biotechnology
Life Science
Therapeutics
$135M11 May 2021 Cambridge, Massachusetts, United States

GH Research

$125M12 Apr 2021 Dublin, County Dublin, Ireland

Graphite Bio

Biotechnology
$150M15 Mar 2021 South San Francisco, California, United States
News
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

Biotech Company Nuvalent Raises $135 Million

– Nuvalent is a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer.
– The company raised $135m in Series B funding.
Bain Capital Life Sciences led the round and was joined by Deerfield Management, Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus Capital Management LLC, and Logos Capital.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Venrock Healthcare Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: